Viral Hepatitis

You have full text access to this OnlineOpen article

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients†‡

  1. Thomas Berg1,§,*,
  2. Viola Weich1,
  3. Gerlinde Teuber2,
  4. Hartwig Klinker3,
  5. Bernd Möller4,
  6. Jens Rasenack5,
  7. Holger Hinrichsen6,
  8. Tilman Gerlach7,
  9. Ulrich Spengler8,
  10. Peter Buggisch9,
  11. Heike Balk10,
  12. Myrga Zankel10,
  13. Konrad Neumann11,
  14. Christoph Sarrazin2,
  15. Stefan Zeuzem2

Article first published online: 6 APR 2009

DOI: 10.1002/hep.22991

Issue

Hepatology

Hepatology

Volume 50, Issue 2, pages 369–377, August 2009

Additional Information

How to Cite

Berg, T., Weich, V., Teuber, G., Klinker, H., Möller, B., Rasenack, J., Hinrichsen, H., Gerlach, T., Spengler, U., Buggisch, P., Balk, H., Zankel, M., Neumann, K., Sarrazin, C. and Zeuzem, S. (2009), Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients. Hepatology, 50: 369–377. doi: 10.1002/hep.22991

Author Information

  1. 1

    Universitätsklinikum Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany

  2. 2

    Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universität Frankfurt a.M., Frankfurt, Germany

  3. 3

    Medizinische Klinik und Poliklinik II der Universität Würzburg, Würzburg, Germany

  4. 4

    Hepatologische Schwerpunktpraxis Charlottenburger Str., Berlin, Germany

  5. 5

    Medizinische Universitätsklinik Freiburg, Freiburg, Germany

  6. 6

    Klinikum der Christian-Albrechts-Universität, Kiel, Germany

  7. 7

    Klinikum Großhadern, Ludwig-Maximilians-Universität, München, Germany

  8. 8

    Medizinische Universitätsklinik II, Bonn, Germany

  9. 9

    Medizinische Universitätsklinik Eppendorf, Hamburg, Germany

  10. 10

    Essex Pharma GmbH, München, Germany

  11. 11

    Charité, Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany

  1. §

    fax: (49)-30-450-553903.

*Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

  1. †

    Presented in part at the Annual Meetings of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases in 2006.

  2. ‡

    Potential conflicts of interest: Dr. Berg advises, is on the speakers' bureau of, and received grants from Roche and Schering-Plough. Dr. Klinker is a consultant for and lectures for Bristol-Myers Squibb, and GlaxoSmithKline. He also lectures for Boehringer Ingelheim, Roche, Gilead, and Tibotec. He lectures for and received grants from Essex. He is a consultant for Merck Sharp & Dohme and received grants from Abbott. Dr. Buggisch is on the speakers' bureau of Roche. Dr. Sarrazin is on the speakers' bureau of and received grants from Essex. Dr. Zeuzem is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche and Schering-Plough.

Publication History

  1. Issue published online: 29 JUL 2009
  2. Article first published online: 6 APR 2009
  3. Accepted manuscript online: 6 APR 2009 12:00AM EST
  4. Manuscript Accepted: 15 MAR 2009
  5. Manuscript Received: 25 OCT 2008

Funded by

  • Essex Pharma (Munich, Germany), a subsidiary of Schering-Plough (Kenilworth, NJ)
  • Bayer Diagnostics
  • German Competence Network for Viral Hepatitis (Kompetenznetz Hepatitis, Hep-Net), funded by the German Ministry of Education and Research. Grant Number: 01 KI 0102
  • VIRGIL European Network of Excellence Combating Viral Resistance to Treatments

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (394K)

References

  • 1
    Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351–355.
  • 2
    Lauer GM, Walker BD. Hepatitis C virus infection. N Eng J Med 2001; 345: 41–52.
  • 3
    Alter MJ. Epidemiology of hepatitis C. HEPATOLOGY 1997; 26: 62S–65S.
    Direct Link:
  • 4
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–567.
  • 5
    Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41–48.
  • 6
    Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444–2451.
  • 7
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 8
    Mangia A. Short-duration therapy for hepatitis C: suitable for all? J Viral Hepat 2007; 14: 221–227.
    Direct Link:
  • 9
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522–527.
  • 10
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.
  • 11
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513–1520.
    Direct Link:
  • 12
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964–970.
  • 13
    Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. The European Medicines Agency: London; 2000.
  • 14
    Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007; 14(Suppl 1): 82–88.
    Direct Link:
  • 15
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954–960.
    Direct Link:
  • 16
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451–458.
  • 17
    Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. HEPATOLOGY 2008; 47: 1884–1893.
    Direct Link:
  • 18
    Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. HEPATOLOGY 2006; 44: 360–367.
    Direct Link:
  • 19
    Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, et al. Importance of a minimal residual viremia for the relapse prediction in HCV type 1 patients receiving standard or individualized treatment duration [Abstract 179]. HEPATOLOGY 2007; 46(Suppl): 317A.
  • 20
    Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, et al. Time to HCV RNA negativation in hepatitis C virus (HCV) type 1-infection during PEG-interferon alpha-2B plus ribavirin therapy: differences in relation to the assay sensitivity (Indiv-1 study group) [Abstract 272]. HEPATOLOGY 2007; 46(Suppl): 360A.
  • 21
    Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13(Suppl 1): 9–16.
  • 22
    Berg T, Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther 2008; 13(Suppl 1): 17–22.
  • 23
    Zeuzem S, Fried MW, Reddy KR, et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa 2a (40 KD) (Pegasys) plus ribavirin (Copegus) [Abstract 2009]. 2006; 44(Suppl): 267A.
  • 24
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086–1097.
  • 25
    Sanchez-Tapias JM, Diago M, Escartin P, Enríquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451–460.
  • 26
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. HEPATOLOGY 2007; 46: 1688–1694.
    Direct Link:
  • 27
    Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. HEPATOLOGY 2008; 47: 43–50.
    Direct Link:
View Full Article with Supporting Information (HTML) Get PDF (394K)